Tadalafil for benign prostatic hyperplasia.
Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor licensed for the treatment of erectile dysfunction (ED) in adult males (Cialis-Lilly) and for the management of pulmonary arterial hypertension (Adcirca-Lilly).(1) The 5mg tablet was licensed in November 2012 for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males (Cialis 5mg-Lilly).(2) In this article, we consider the evidence for tadalafil and how its use fits with current management strategies for BPH.